MID‐Frail News returns with this Special Issue to report on the project development meeting held in Tudela de Navarra, Spain from 16–19 April. This meeting saw the driving force behind the MID‐Frail project gathered at the Universidad Pública de Navarra (UPNA) in northern Spain, as they prepared to initiate the MID‐Frail programme intervention later this year. Professor Mikel Izquierdo of the Department of Health Sciences at UPNA provided a warm welcome to over 30 scientists, physicians and analysts from the 16 organisations in seven countries across Europe (Belgium, Germany, France, Spain, Italy, the Czech Republic and the UK) who are taking part in the MID‐Frail study.
The first day of the meeting focused on the revised version of the Study Protocol. MID‐Frail co‐ordinators Professor Leo Rodríguez Mañas and Professor Alan Sinclair were joined by Project Manager Maria Sanchiz from the Spanish Clinical Research Network (Caiber), who led a discussion of the latest refinements to this very important document. During a lively debate a number of important issues were raised and appropriate actions agreed upon. This session highlighted the need to plan well ahead in a study of 4‐years duration. The progress made is summarised in our consortium newsletter [1].
Team coordination is crucial to project delivery across consortium with such ambitious goals.The importance of the MID‐Frail study must be reflected in the development of a strong brand identity. Brand‐defining activities that are already underway include construction of the MID‐Frail homepage [2]. Our vision is to advance the impact of ageing research in meeting current and emerging challenges.
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
ive years ago I was lucky enough to be involved in a project that resulted in publications
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
